These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 11512277

  • 1. A simple procedure for synthesis of roxindole, a dopamine D2-receptor agonist.
    Csende F.
    Arch Pharm (Weinheim); 2001 Jul; 334(7):253-4. PubMed ID: 11512277
    [Abstract] [Full Text] [Related]

  • 2. A straightforward synthetic approach for roxindole.
    Lange JH, de Jong JC, Sanders HJ, Visser GM, Kruse CG.
    Bioorg Med Chem Lett; 1999 Apr 05; 9(7):1055-6. PubMed ID: 10230639
    [Abstract] [Full Text] [Related]

  • 3. Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors.
    Newman-Tancredi A, Cussac D, Audinot V, Millan MJ.
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun 05; 359(6):447-53. PubMed ID: 10431754
    [Abstract] [Full Text] [Related]

  • 4. Sensitivity of dopamine D2 receptors following long-term treatment with roxindole.
    Seyfried CA, Bartoszyk GD.
    Eur J Pharmacol; 1994 May 12; 257(1-2):67-72. PubMed ID: 7915991
    [Abstract] [Full Text] [Related]

  • 5. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD, Harting J, Minck KO.
    J Pharmacol Exp Ther; 1996 Jan 12; 276(1):41-8. PubMed ID: 8558454
    [Abstract] [Full Text] [Related]

  • 6. 3-[[(4-Aryl-1-piperazinyl)alkyl]cyclohexyl]-1H-indoles as dopamine D2 partial agonists and autoreceptor agonists.
    Wustrow DJ, Smith WJ, Corbin AE, Davis MD, Georgic LM, Pugsley TA, Whetzel SZ, Heffner TG, Wise LD.
    J Med Chem; 1997 Jan 17; 40(2):250-9. PubMed ID: 9003524
    [Abstract] [Full Text] [Related]

  • 7. Involvement of dopamine D2 and 5-HT1A receptors in roxindole-induced antinociception.
    Ninan I, Kulkarni SK.
    Indian J Exp Biol; 1999 Mar 17; 37(3):234-7. PubMed ID: 10641151
    [Abstract] [Full Text] [Related]

  • 8. Fused azaindole derivatives: molecular design, synthesis and in vitro pharmacology leading to the preferential dopamine D3 receptor agonist FAUC 725.
    Löber S, Hübner H, Gmeiner P.
    Bioorg Med Chem Lett; 2002 Sep 02; 12(17):2377-80. PubMed ID: 12161137
    [Abstract] [Full Text] [Related]

  • 9. Di- and trisubstituted pyrazolo[1,5-a]pyridine derivatives: synthesis, dopamine receptor binding and ligand efficacy.
    Löber S, Aboul-Fadl T, Hübner H, Gmeiner P.
    Bioorg Med Chem Lett; 2002 Feb 25; 12(4):633-6. PubMed ID: 11844688
    [Abstract] [Full Text] [Related]

  • 10. The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients.
    Gründer G, Wetzel H, Hillert A, Jochum E, Hiemke C, Benkert O.
    Psychopharmacology (Berl); 1995 Feb 25; 117(4):472-8. PubMed ID: 7604150
    [Abstract] [Full Text] [Related]

  • 11. Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression.
    Gründer G, Wetzel H, Hammes E, Benkert O.
    Psychopharmacology (Berl); 1993 Feb 25; 111(1):123-6. PubMed ID: 7870927
    [Abstract] [Full Text] [Related]

  • 12. Fancy bioisosteres: synthesis and dopaminergic properties of the endiyne FAUC 88 as a novel non-aromatic D3 agonist.
    Lenz C, Haubmann C, Hübner H, Boeckler F, Gmeiner P.
    Bioorg Med Chem; 2005 Jan 03; 13(1):185-91. PubMed ID: 15582463
    [Abstract] [Full Text] [Related]

  • 13. Synthesis of 2-fluoro-11-hydroxy-N-propylnoraporphine: a potential dopamine D2 agonist.
    Zhang A, Csutoras C, Zong R, Neumeyer JL.
    Org Lett; 2005 Jul 21; 7(15):3239-42. PubMed ID: 16018630
    [Abstract] [Full Text] [Related]

  • 14. Endocrine characterization of the new dopamine autoreceptor agonist roxindole.
    Wiedemann K, Kellner M.
    Exp Clin Endocrinol; 1994 Jul 21; 102(4):284-8. PubMed ID: 7813599
    [Abstract] [Full Text] [Related]

  • 15. New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template.
    Mewshaw RE, Verwijs A, Shi X, McGaughey GB, Nelson JA, Mazandarani H, Brennan JA, Marquis KL, Coupet J, Andree TH.
    Bioorg Med Chem Lett; 1998 Oct 06; 8(19):2675-80. PubMed ID: 9873601
    [Abstract] [Full Text] [Related]

  • 16. Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists.
    Elsner J, Boeckler F, Heinemann FW, Hübner H, Gmeiner P.
    J Med Chem; 2005 Sep 08; 48(18):5771-9. PubMed ID: 16134944
    [Abstract] [Full Text] [Related]

  • 17. Synthesis of 3-Azidopiperidine Skeleton Employing Ceric Ammonium Nitrate (CAN)-Mediated Regioselective Azidoalkoxylation of Enol Ether: Total Synthesis of D2 Receptor Agonist (±)-Quinagolide.
    Chavan SP, Kadam AL, Lasonkar PB, Gonnade RG.
    Org Lett; 2018 Nov 16; 20(22):7011-7014. PubMed ID: 30394757
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Synthesis and pharmacological evaluation of substituted naphth[1,2,3-de]isoquinolines (dinapsoline analogues) as D1 and D2 dopamine receptor ligands.
    Qandil AM, Lewis MM, Jassen A, Leonard SK, Mailman RB, Nichols DE.
    Bioorg Med Chem; 2003 Apr 03; 11(7):1451-64. PubMed ID: 12628671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.